Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature.
Publication
, Journal Article
Diehl, LF; Banks, A; Carter, W; Klein, MA; Muss, HB; Weiss, RB
Published in: Cancer Chemother Pharmacol
1988
A case of fatal dilated cardiomyopathy induced by esorubicin (ESO) at a total dose of 740 mg/m2, given in 27 doses over 650 days, is reported. The sudden onset, rapid clinical deterioration, and fatal outcome are detailed. The outcome was not predicted by serial rest ejection fractions or clinical signs. The data from animal studies, phase 1 and phase 2 clinical testing, are reviewed, demonstrating the almost complete absence of reports of ESO-induced cardiotoxicity. Studies reviewing ejection fractions and myocardial biopsy scores show that ESO can be cardiotoxic and may produce fatal dilated cardiomyopathy.
Duke Scholars
Published In
Cancer Chemother Pharmacol
DOI
ISSN
0344-5704
Publication Date
1988
Volume
21
Issue
4
Start / End Page
347 / 350
Location
Germany
Related Subject Headings
- Oncology & Carcinogenesis
- Middle Aged
- Lung Neoplasms
- Humans
- Female
- Drug Evaluation
- Doxorubicin
- Cardiomyopathies
- 1115 Pharmacology and Pharmaceutical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Diehl, L. F., Banks, A., Carter, W., Klein, M. A., Muss, H. B., & Weiss, R. B. (1988). Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature. Cancer Chemother Pharmacol, 21(4), 347–350. https://doi.org/10.1007/BF00264203
Diehl, L. F., A. Banks, W. Carter, M. A. Klein, H. B. Muss, and R. B. Weiss. “Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature.” Cancer Chemother Pharmacol 21, no. 4 (1988): 347–50. https://doi.org/10.1007/BF00264203.
Diehl LF, Banks A, Carter W, Klein MA, Muss HB, Weiss RB. Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature. Cancer Chemother Pharmacol. 1988;21(4):347–50.
Diehl, L. F., et al. “Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature.” Cancer Chemother Pharmacol, vol. 21, no. 4, 1988, pp. 347–50. Pubmed, doi:10.1007/BF00264203.
Diehl LF, Banks A, Carter W, Klein MA, Muss HB, Weiss RB. Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature. Cancer Chemother Pharmacol. 1988;21(4):347–350.
Published In
Cancer Chemother Pharmacol
DOI
ISSN
0344-5704
Publication Date
1988
Volume
21
Issue
4
Start / End Page
347 / 350
Location
Germany
Related Subject Headings
- Oncology & Carcinogenesis
- Middle Aged
- Lung Neoplasms
- Humans
- Female
- Drug Evaluation
- Doxorubicin
- Cardiomyopathies
- 1115 Pharmacology and Pharmaceutical Sciences